Dual Intratumoral Redox/Enzyme-Responsive NO-Releasing Nanomedicine for the Specific, High-Efficacy, and Low-Toxic Cancer Therapy
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Chemotherapy suffers numbers of limitations including poor drug solubility, nonspecific biodistribution, and inevitable adverse effects on normal tissues. Tumor‐targeted delivery and intratumoral stimuli‐responsive release of drugs by nanomedicines are considered to be highly promising in solving these problems. Compared with traditional chemotherapeutic drugs, high concentration of nitric oxide (NO) exhibits unique anticancer effects. The development of tumor‐targeting and intratumoral microenvironment‐responsive NO‐releasing nanomedicines is highly desired. Here a novel kind of organic–inorganic composite nanomedicine (QM‐NPQ@PDHNs) is presented by encapsulating a glutathione S‐transferases π (GSTπ)‐responsive drug O2‐(2,4‐dinitro‐5‐{[2‐(β‐d‐galactopyranosyl olean‐12‐en‐28‐oate‐3‐yl)‐oxy‐2‐oxoethyl] piperazine‐1‐yl} phenyl) 1‐(methylethanolamino)diazen‐1‐ium‐1,2‐dilate (NPQ) as NO donor and an aggregation‐induced‐emission (AIE) red fluorogen QM‐2 into the cores of the hybrid nanomicelles (PEGylated disulfide‐doped hybrid nanocarriers (PDHNs)) with glutathione (GSH)‐responsive shells. The QM‐NPQ@PDHN nanomedicine is able to respond to the intratumoral over‐expressed GSH and GSTπ, resulting in the responsive biodegradation of the protective organosilica shell and NPQ release, and subsequent NO release within the tumor, respectively, and thus normal organs remain unaffected. This work demonstrates a paradigm of dual intratumoral redox/enzyme‐responsive NO‐release nanomedicine for tumor‐specific and high‐efficacy cancer therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This makes glutathione an excellent target for drug delivery in cancer therapy [211,212,213,214,215].”
From Recent Advances in Nanomicelles Delivery Systems. (2020) · cites this paper as [215]
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
Designing dendrimers for biological applications
Lee, C. C., MacKay, J. A., Fréchet, J. M. J., & Szoka, F. C. (2005) · Nature Biotechnology · doi:10.1038/nbt1171 · Cited by 2,043
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
The role of nitric oxide in tumour progression
Fukumura, D., Kashiwagi, S., & Jain, R. K. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1910 · Cited by 1,259
Advanced drug delivery devices via self-assembly of amphiphilic block copolymers
Rösler, A., Vandermeulen, G. W. M., & Klok, H.-A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.026 · Cited by 688
Hu, X., Hu, J., Tian, J., Ge, Z., Zhang, G., Luo, K., & Liu, S. (2013) · Journal of the American Chemical Society · doi:10.1021/ja409686x · Cited by 605
Drug self-delivery systems for cancer therapy
Qin, S.-Y., Zhang, A.-Q., Cheng, S.-X., Rong, L., & Zhang, X.-Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.016 · Cited by 532
Sun, H., Guo, B., Cheng, R., Meng, F., Liu, H., & Zhong, Z. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.051 · Cited by 438
Chung, J. E., Tan, S., Gao, S. J., Yongvongsoontorn, N., Kim, S. H., Lee, J. H., Choi, H. S., Yano, H., Zhuo, L., Kurisawa, M., et al. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.208 · Cited by 412
Kim, H., Kim, S., Park, C., Lee, H., Park, H. J., & Kim, C. (2010) · Advanced Materials · doi:10.1002/adma.201001417 · Cited by 356
Prodrug-based nanoparticulate drug delivery strategies for cancer therapy
Luo, C., Sun, J., Sun, B., & He, Z. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.008 · Cited by 352
Bhattacharyya, J., Bellucci, J. J., Weitzhandler, I., McDaniel, J. R., Spasojevic, I., Li, X., Lin, C.-C., Chi, J.-T. A., & Chilkoti, A. (2015) · Nature Communications · doi:10.1038/ncomms8939 · Cited by 227
Interfacing Materials Science and Biology for Drug Carrier Design
Such, G. K., Yan, Y., Johnston, A. P. R., Gunawan, S. T., & Caruso, F. (2015) · Advanced Materials · doi:10.1002/adma.201405084 · Cited by 220
Disulfide-containing parenteral delivery systems and their redox-biological fate
Brülisauer, L., Gauthier, M. A., & Leroux, J.-C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.012 · Cited by 190
Creation of Pure Nanodrugs and Their Anticancer Properties
Kasai, H., Murakami, T., Ikuta, Y., Koseki, Y., Baba, K., Oikawa, H., Nakanishi, H., Okada, M., Shoji, M., Ueda, M., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201204596 · Cited by 177
Managing drug resistance in cancer: lessons from HIV therapy
Bock, C., & Lengauer, T. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3297 · Cited by 170
McQuade, L. E., & Lippard, S. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.10.004 · Cited by 159
Therapeutic Nanocarriers with Hydrogen Peroxide-Triggered Drug Release for Cancer Treatment
Liu, J., Pang, Y., Zhu, Z., Wang, D., Li, C., Huang, W., Zhu, X., & Yan, D. (2013) · Biomacromolecules · doi:10.1021/bm4002574 · Cited by 151
Zeng, X., Morgenstern, R., & Nyström, A. M. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.042 · Cited by 136
Dong, D., Xiang, B., Gao, W., Yang, Z., Li, J., & Qi, X. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.018 · Cited by 130
Ding, Y., Su, S., Zhang, R., Shao, L., Zhang, Y., Wang, B., Li, Y., Chen, L., Yu, Q., Wu, Y. F., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.053 · Cited by 118
Self-citationMMP-2 responsive polymeric micelles for cancer-targeted intracellular drug delivery
Chen, W.-H., Luo, G.-F., Lei, Q., Jia, H.-Z., Hong, S., Wang, Q.-R., Zhuo, R.-X., & Zhang, X.-Z. (2015) · Chemical Communications · doi:10.1039/c4cc07563c · Cited by 115
Synergistic gene and drug tumor therapy using a chimeric peptide
Han, K., Chen, S., Chen, W., Lei, Q., Liu, Y., Zhuo, R., & Zhang, X. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.010 · Cited by 113
Tang, S., Meng, Q., Sun, H., Su, J., Yin, Q., Zhang, Z., Yu, H., Chen, L., Gu, W., & Li, Y. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.005 · Cited by 104
Self-citationChen, L., Zhang, Y., Kong, X., Lan, E., Huang, Z., Peng, S., Kaufman, D. L., & Tian, J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800167u · Cited by 101
Self-citationLi, Y., Shao, A., Wang, Y., Mei, J., Niu, D., Gu, J., Shi, P., Zhu, W., Tian, H., & Shi, J. (2016) · Advanced Materials · doi:10.1002/adma.201504782 · Cited by 98
Self-citationSaavedra, J. E., Srinivasan, A., Buzard, G. S., Davies, K. M., Waterhouse, D. J., Inami, K., Wilde, T. C., Citro, M. L., Cuellar, M., Deschamps, J. R., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050700k · Cited by 92
Shao, A., Xie, Y., Zhu, S., Guo, Z., Zhu, S., Guo, J., Shi, P., James, T. D., Tian, H., & Zhu, W. (2015) · Angewandte Chemie · doi:10.1002/ange.201501478 · Cited by 91
Self-citationZeng, X., Zhang, Y., & Nyström, A. M. (2012) · Biomacromolecules · doi:10.1021/bm301281k · Cited by 89
Self-citationPreparation of Uniform, Water‐Soluble, and Multifunctional Nanocomposites with Tunable Sizes
Niu, D., Li, Y., Ma, Z., Diao, H., Gu, J., Chen, H., Zhao, W., Ruan, M., Zhang, Y., & Shi, J. (2010) · Advanced Functional Materials · doi:10.1002/adfm.200901493 · Cited by 82
Self-citationChuang, E., Lin, C.-C., Chen, K., Wan, D., Lin, K., Ho, Y., Lin, P.-Y., & Sung, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.040 · Cited by 68
Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies
Papot, S., Tranoy‐Opalinski, I., Tillequin, F., Florent, J., & GESSON, J. ‐. (2002) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023354173 · Cited by 66
Tanabe, K., Zhang, Z., Itô, T., Hatta, H., & Nishimoto, S. (2007) · Organic & Biomolecular Chemistry · doi:10.1039/b711244k · Cited by 63
Fu, J., Liu, L., Huang, Z., Lai, Y., Ji, H., Peng, S., Tian, J., & Zhang, Y. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400393u · Cited by 60
Self-citationYang, Y., Yue, C., Han, Y., Zhang, W., He, A., Zhang, C., Yin, T., Zhang, Q., Zhang, J., Yang, Y., et al. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201601369 · Cited by 58
Disulfide-functional poly(amido amine)s with tunable degradability for gene delivery
Elzes, M. R., Akeroyd, N., Engbersen, J. F. J., & Paulusse, J. M. J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.021 · Cited by 55
Shao, K., Zhang, Y. X., Ding, N., Huang, S., Wu, J., Li, J., Yang, C., Leng, Q., Ye, L., Lou, J., et al. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201400214 · Cited by 54
Self-citationIn situ activation of a doxorubicin prodrug using imaging-capable nanoparticles
Khan, I. A., Agris, P. F., Yigit, M. V., & Royzen, M. (2016) · Chemical Communications · doi:10.1039/c6cc01024e · Cited by 54
Hayashi, K., Maruhashi, T., Nakamura, M., Sakamoto, W., & Yogo, T. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201603394 · Cited by 43
Sayed, S. E., Giménez, C., Aznar, E., Martínez‐Máñez, R., Sancenón, F., & Licchelli, M. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02083a · Cited by 41
Nanoscaled Boron-Containing Delivery Systems and Therapeutic Agents for Cancer Treatment
Wang, J., Wu, W. H., & Jiang, X. (2015) · Nanomedicine · doi:10.2217/nnm.14.213 · Cited by 39
Behzadi, S., Steinmann, M., Estupiñán, D., Landfester, K., & Crespy, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.040 · Cited by 37
Acid-cleavable ketal containing poly(β-amino ester) for enhanced siRNA delivery
Guk, K., Lim, H., Kim, B.-K., Hong, M., Khang, G., & Lee, D. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.06.021 · Cited by 36
Zhang, P., Lu, J., Huang, Y., Zhao, W., Zhang, Y., Zhang, X., Li, J., Venkataramanan, R., Gao, X., & Li, S. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9536-9 · Cited by 27
Self-citationSaha, S., & Loo, S. C. J. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00086f · Cited by 24
Leriche, G., Nothisen, M., Baumlin, N., Muller, C. D., Bagnard, D., Rémy, J.-S., Jacques, S. A., & Wagner, A. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00280 · Cited by 23
The Design of Selectively-Activated Prodrugs for Cancer Chemotherapy
Denny, W. A. (1996) · Current Pharmaceutical Design · doi:10.2174/1381612802666220921174359 · Cited by 20
PEGylated Fmoc–Amino Acid Conjugates as Effective Nanocarriers for Improved Drug Delivery
Zhang, P., Huang, Y., Kwon, Y. T., & Li, S. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00157 · Cited by 17
Zhao, W., Zhang, H., Chang, S., Gu, J., Li, Y., Li, L., & Shi, J. (2012) · RSC Advances · doi:10.1039/c2ra20166f · Cited by 14
Self-citation
Research works printed but not linked: 1
- Matsumura Y., 1986, Cancer Res., 46, 6387
Cited by
Recent Advances in Nanomaterial‐Assisted Combinational Sonodynamic Cancer Therapy
Liang, S., Deng, X., Ma, P., Cheng, Z., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202003214 · Cited by 598
Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics
Gong, F., Yang, N., Wang, X., Zhao, Q., Chen, Q., Liu, Z., & Cheng, L. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100851 · Cited by 359
Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery
Majumder, J., & Minko, T. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1828339 · Cited by 348
Strategies for engineering advanced nanomedicines for gas therapy of cancer
Wang, Y., Yang, T., & He, Q. (2020) · National Science Review · doi:10.1093/nsr/nwaa034 · Cited by 291
Self-citationBiomedical application of graphene: From drug delivery, tumor therapy, to theranostics
Song, S., Shen, H., Wang, Y., Chu, X., Xie, J., Zhou, N., & Shen, J. (2020) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2019.110596 · Cited by 233
Self-citation
Metadata
- Authors
- Jia, X., Zhang, Y., Zou, Y., Wang, Y., Niu, D., He, Q., Huang, Z., Zhu, W., Tian, H., Shi, J., & Li, Y.
- Affiliations
- East China University of Science and Technology (CN)
- China Pharmaceutical University (CN)
- Shenzhen University (CN)
- Corresponding author
- Huang, Zhangjian
- Li, Yongsheng
- ORCID
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2018-06-11
- Volume
- 30
- Issue
- 30
- Pages
- e1704490-e1704490
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2808401691
- Cited by
- 232
- References
- 52
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 23 · 2023: 29 · 2022: 33 · 2021: 41 · 2020: 34 · 2019: 41 · 2018: 7
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Materials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (51621002, 51572083, 51461165202, 51472085)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Materials Chemistry › Luminescence and Fluorescent Materials
- Keywords
- nitric oxide delivery, nitric oxide donors, glutathione S-transferase pi, glutathione-responsive release, redox-responsive drug release, anticancer drug delivery, cancer therapy
- MeSH terms
- Humans, Neoplasms, Nitric Oxide, Oxidation-Reduction, Tissue Distribution, Nanomedicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.